IP Library Patent Application 15875373
Patent Application
App. No. 15/875,373

METHOD OF PRODUCING BIOLOGICALLY ACTIVE VITAMIN K DEPENDENT PROTEINS BY RECOMBINANT METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/875,373
Abstract

The invention relates to commercially viable methods for producing biologically active vitamin R dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent γ-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.

Claims (34)

1 .- 35 . (canceled)

36 . A method of producing a mammalian cell that produces a high level of recombinant biologically active vitamin K dependent protein comprising transfecting a mammalian cell with:

(i) a gene encoding a vitamin K dependent protein,

(ii) a gene encoding vitamin K dependent epoxide reductase (VKOR), and

(iii) a gene encoding vitamin K dependent γ-glutamyl carboxylase (VKGC); wherein the gene encoding the vitamin K dependent protein is operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, and

wherein the cell produces at least about 15 mg/L of a recombinant vitamin K dependent protein, and wherein at least 60% of the recombinant vitamin K dependent protein is biologically active.

37 . The method of claim 36 , wherein the vitamin K dependent protein is selected from the group consisting of Factor II, Factor VII, Factor IX, Factor X, Protein C and Protein S.

38 . The method of claim 36 , wherein the mammalian cell further comprises a gene encoding paired basic amino acid converting enzyme (PACE) operably liked to a promoter.

39 . The method of claim 36 , wherein at least about 75% of the glutamic acid residues within the gla-domain of the recombinant biologically active vitamin K dependent protein are gamma carboxylated.

40 . The method of claim 36 , wherein the mammalian cell is a CHO cell or HEK 293 cell.

41 . The method of claim 36 , wherein at least 70% or at least 80% of the recombinant vitamin K dependent protein is biologically active.

42 . The method of claim 36 , wherein (ii) and/or (iii) are operably linked to the Chinese hamster elongation factor 1-α (CHEF1) promoter.

43 . The method of claim 36 , wherein (ii) and/or (iii) are operably linked to a promoter that is not the Chinese hamster elongation factor 1-α (CHEF1) promoter.

44 . The method of claim 36 , wherein (ii) and (iii) are operably linked to different promoters or the same promoter.

45 . A mammalian cell that produces a high level of recombinant biologically active vitamin K dependent protein, wherein the cell comprises:

(i) a gene encoding a vitamin K dependent protein,

(ii) a gene encoding vitamin K dependent epoxide reductase (VKOR), and

(iii) a gene encoding vitamin K dependent γ-glutamyl carboxylase (VKGC);

wherein the gene encoding the vitamin K dependent protein is operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, and

wherein the cell produces at least about 15 mg/L of a recombinant vitamin K dependent protein, and wherein at least 60% of the recombinant vitamin K dependent protein is biologically active.

46 . The cell of claim 45 , wherein the vitamin K dependent protein is selected from the group consisting of Factor II, Factor VII, Factor IX, Factor X, Protein C and Protein S.

47 . The cell of claim 45 , wherein the cell further comprises a gene encoding paired basic amino acid converting enzyme (PACE) operably liked to a promoter.

48 . The cell of claim 45 , wherein at least about 75% of the glutamic acid residues within the gla-domain of the recombinant biologically active vitamin K dependent protein are gamma carboxylated.

49 . The cell of claim 45 , wherein the cell is a CHO cell or a HEK 293 cell.

50 . The cell of claim 45 , wherein at least 70% or at least 80% of the recombinant vitamin K dependent protein is biologically active.

51 . The cell of claim 45 , wherein (ii) and/or (iii) are operably linked to the Chinese hamster elongation factor 1-α (CHEF1) promoter.

52 . The cell of claim 45 , wherein (ii) and/or (iii) are operably linked to a promoter that is not the Chinese hamster elongation factor 1-α (CHEF1) promoter.

53 . The cell of claim 45 , wherein (ii) and (iii) are operably linked to different promoters or to the same promoter.

54 . A method of producing a high level of recombinant biologically active vitamin K dependent protein comprising:

(a) transfecting mammalian cells with (i) a gene encoding the vitamin K dependent protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, and, (ii) a gene encoding vitamin K dependent epoxide reductase (VKOR) operably linked to a CHEF1promoter; and

(b) harvesting recombinant vitamin K dependent protein produced by the mammalian cells; wherein the mammalian cells produce at least about 15 mg/L of the recombinant vitamin K dependent protein, and wherein at least 60% of the recombinant vitamin K dependent protein is biologically active.

55 . A method of producing a high level of recombinant biologically active vitamin K dependent protein comprising:

(a) transfecting mammalian cells with (i) a gene encoding the vitamin K dependent protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, and, (ii) a gene encoding vitamin K dependent y-glutamyl carboxylase (VKGC) operably linked to a CHEF1 promoter; and

(b) harvesting recombinant vitamin K dependent protein produced by the mammalian cells; wherein the mammalian cells produce at least about 15 mg/L of the recombinant vitamin K dependent protein, and wherein at least 60% of the recombinant vitamin K dependent protein is biologically active.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2023
From: MIDCAP FINANCIAL TRUST
To: MEDEXUS PHARMA INC.; MEDEXUS PHARMACEUTICALS INC.; MI ACQUISITIONS, INC.,; APTEVO BIOTHERAPEUTICS LLC,
Reel/Frame 063049/0761 →
SECURITY AGREEMENT Recorded Mar 8, 2023
From: APTEVO BIOTHERAPEUTICS LLC
To: BANK OF MONTREAL, AS ADMINISTRATIVE AGENT
Reel/Frame 062992/0829 →
SECURITY INTEREST (REVOLVING) Recorded May 8, 2020
From: MEDEXUS PHARMACEUTICALS INC.; MEDEXUS INC.; MEDEXUS PHARMA, INC.; MI ACQUISITIONS, INC.; APTEVO BIOTHERAPEUTICS LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 052617/0579 →
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: APTEVO THEAPEUTICS INC.; APTEVO BIOTHERAPEUTICS LLC; APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 052039/0258 →
SECURITY INTEREST Recorded Mar 6, 2020
From: MEDEXUS PHARMACEUTICALS INC.; MEDEXUS INC.; MEDEXUS PHARMA, INC.; MI ACQUISITIONS, INC.; APTEVO BIOTHERAPEUTICS LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 052039/0633 →
SECURITY INTEREST Recorded Feb 7, 2019
From: APTEVO THERAPEUTICS INC.; APTEVO BIOTHERAPEUTICS INC.; APTEVO RESEARCH AND DEVELOPMENT LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 048270/0813 →